Last edition
News about "Sabirnetug "
Acumen Pharmaceuticals Appoints New Chief Regulatory Officer and Head of Quality
Dr. Schacterle brings over 30 years of experience in regulatory affairs, quality assurance, and therapeutic development to Acumen, with a focus on diseases of the central nervous system.
Sabirnetug | 07/11/2024 | By Aishwarya
Acumen Pharma Extends Partnership with Lonza to Support Manufacturing of Sabirnetug
Sabirnetug is the first humanized monoclonal antibody to clinically demonstrate selective target engagement of AβOs in AD patients.
Sabirnetug | 30/09/2024 | By Aishwarya
Acumen Announces New Findings from Phase 1 INTERCEPT-AD Study at AAIC 2024
Acumen Pharmaceuticals, Inc. has published new findings from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193).
Sabirnetug | 29/07/2024 | By Aishwarya
Acumen Announces First Patient Dosed in ALTITUDE-AD
Acumen Pharmaceuticals, Inc. has announced that the first patient has been dosed with sabirnetug (ACU193) in the ALTITUDE-AD Phase 2 clinical trial designed to evaluate the clinical efficacy and safety of sabirnetug in patients with early AD.
Sabirnetug | 08/05/2024 | By Aishwarya | 125
Acumen Pharmaceuticals Join Hands with Lonza to Bolster Sabirnetug Production
Acumen Pharmaceuticals has signed a partnership agreement with Lonza, a global partner to the pharmaceutical, biotech, and nutraceutical markets.
Sabirnetug | 05/04/2024 | By Aishwarya | 231
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy